With Democrats now poised to gain control of both chambers of Congress, AMCP published the following deck to outline the impacts of the 2026 midterm election on federal health policy.
AMCP Comment Letter on Medicare Drug Price Negotiation Program Draft Guidance
AMCP recognizes the importance of efforts to make prescription drugs more affordable for Medicare beneficiaries and urges CMS to continually and rigorously oversee the program’s implementation and its broader effects to ensure that it does not unintentionally hinder innovation and the development of new therapies. CMS should monitor the downstream impact of the Medicare Drug Price Negotiation Program on innovation and drug development and take appropriate action as needed to ensure that the United States remains the leader in pharmaceutical innovation.
Related
Cell & Gene Therapies (CGT) offer potentially curative treatment to patients with chronic and hereditary conditions but carry high price tags. One proposal to overcome such financing challenges is to create a national risk pool.
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare & Medicaid Services (CMS) for the opportunity to provide comments in response to Medicare Drug Price Negotiation Program: Draft Guidance, Manufacturer Effectuation of the Maximum Fair Price in 2028 (Draft Guidance). CMS issued this draft guidance to describe the processes and requirements for manufacturer effectuation of the maximum fair price (MFP) in 2028 for selected drugs payable under Medicare Part B and/or covered under Medicare Part D.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
